Allergy: European Journal of Allergy and Clinical Immunology

publication venue for

Management of anaphylaxis due to COVID‐19 vaccines in the elderly. 76:2952-2964. 2021
Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence”. 76:2663-2672. 2021
Effect of anti‐IL‐5 biologics on weight and body mass index. 76:2913-2916. 2021
Effect of intranasal corticosteroid treatment on allergen‐induced changes in group 2 innate lymphoid cells in allergic rhinitis with mild asthma. 76:2797-2808. 2021
Group 2 innate lymphoid cells in patients with nonasthmatic eosinophilic bronchitis 2021
Detecting immunoglobulins in processed sputa 2021
Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA 2 LEN consensus. 76:2354-2366. 2021
Enlightening human B‐cell diversity. 76:2644-2646. 2021
Local inflammation enables a basophil‐neuronal circuITCH in atopic dermatitis 2021
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence 2021
The food, the bug, and the ugly: A recipe for food‐induced gut pain 2021
Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA. 76:2177-2188. 2021
First contact: Serum amyloid A and pattern recognition in Th2 immunity. 76:2309-2311. 2021
IL‐13 signature in severe adult asthmatics with airway neutrophilia: A new endotype to treat!. 76:1964-1966. 2021
Medical algorithms: Approach to adult asthma exacerbations 2021
Direct and indirect bronchoprovocation tests in dose‐response studies of inhaled corticosteroids: Past, present, and future directions. 76:1679-1692. 2021
Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre‐ and post‐peptide immunotherapy: An open‐label clinical study. 76:1907-1911. 2021
Notch4, uncovering an immunomodulator in allergic asthma 2021
Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report 2021
The global burden of illness of peanut allergy: A comprehensive literature review. 76:1367-1384. 2021
Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?. 76:1294-1297. 2021
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020). 76:689-697. 2021
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐19. 76:735-750. 2021
Dupilumab, severe asthma airway responses, and SARS‐CoV‐2 serology. 76:957-958. 2021
Modeling the conversion between specific IgE test platforms for nut allergens in children and adolescents. 76:831-841. 2021
Obituary: Anthony Barrington Kay (1939‐2020). 76:969-969. 2021
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. 76:168-190. 2021
Asthma exacerbations on benralizumab are largely non‐eosinophilic. 76:375-379. 2021
EAACI Biologicals Guidelines—Recommendations for severe asthma. 76:14-44. 2021
Thinking small: Zinc sensing by the gut epithelium. 76:411-413. 2021
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2. 75:2503-2541. 2020
Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI). 75:2445-2476. 2020
Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement. 75:2440-2444. 2020
Single‐cell RNA analysis: Guiding the treatment of DiHS/DRESS. 75:2713-2715. 2020
Phenotype consensus is required to enable large‐scale genetic consortium studies of food allergy. 75:2383-2387. 2020
The neuroimmunological toll of nutrient absorption. 75:2415-2417. 2020
Exon 8 KIT mutation and pulmonary eosinophilia. 75:2094-2096. 2020
Mining the infant gut microbiota for therapeutic targets against atopic disease. 75:2065-2068. 2020
Sputum and serum immunoglobulins in adult asthmatics with recurrent respiratory tract infections. 75:2105-2108. 2020
Cord blood hemopoietic cell receptor expression is associated with early life atopic risk and lung function. 75:1762-1765. 2020
Correlation between work impairment, scores of rhinitis severity and asthma using the MASK‐air ® App. 75:1672-1688. 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. 75:1043-1057. 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. 75:1023-1042. 2020
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma. 75:1058-1068. 2020
The presence of Aspergillus fumigatus in asthmatic airways is not clearly related to clinical disease severity. 75:1146-1154. 2020
Follicular T cells: From stability to failure. 75:1006-1007. 2020
New paradigm in asthma management: Switching between biologics!. 75:743-745. 2020
Drug‐induced IgG‐neutrophil‐mediated anaphylaxis in humans: Uncovered!. 75:484-485. 2020
Mechanisms and therapeutic strategies for non‐T2 asthma. 75:311-325. 2020
Extract and component‐specific sensitization patterns in Canadian moderate‐to‐severe preschool asthmatics. 74:2519-2521. 2019
2019 ARIA Care pathways for allergen immunotherapy. 74:2087-2102. 2019
Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy. 74:2157-2166. 2019
Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018. 74:2244-2248. 2019
Legends of allergy: Professor A. B. Kay. 74:1588-1590. 2019
ARIApharmacy 2018 “Allergic rhinitis care pathways for community pharmacy”. 74:1219-1236. 2019
Effect of sex on group 2 innate lymphoid cells in the airways of mild and severe asthmatics. 74:1397-1400. 2019
Rapid quantification of sputum eosinophil peroxidase on a lateral flow test strip. 74:1176-1178. 2019
Much ado about Biologicals: Highlights of the Master Class on Biologicals, Prague, 2018. 74:837-840. 2019
IgG1 + B‐cell immunity predates IgE responses in epicutaneous sensitization to foods. 74:165-175. 2019
Human milk oligosaccharide profiles and food sensitization among infants in the CHILD Study. 73:2070-2073. 2018
Sputum cytology during late-phase responses to inhalation challenge with different allergens. 73:1470-1478. 2018
Perspectives in allergen immunotherapy: 2017 and beyond. 73:5-23. 2018
Vitamin D supplementation in primary allergy prevention: Systematic review of randomized and non-randomized studies. 73:37-49. 2018
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. 72:1297-1305. 2017
Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. 72:1035-1042. 2017
Novel approaches and perspectives in allergen immunotherapy. 72:1022-1034. 2017
A dual CysLT1/2antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma. 71:1721-1727. 2016
Global perceptions of food allergy thresholds in 16 countries. 71:1081-1085. 2016
Emotional and behavioral problems in adolescents and young adults with food allergy. 71:532-540. 2016
Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma. 71:571-575. 2016
Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia. 71:567-570. 2016
Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity. 71:283-285. 2016
MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. 70:1372-1392. 2015
Treatment with anti-OX40L or anti-TSLP does not alter the frequency of T regulatory cells in allergic asthmatics. 70:1505-1508. 2015
Comprehensive metabolomics identifies the alarmin uric acid as a critical signal for the induction of peanut allergy. 70:495-505. 2015
Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma. 70:302-309. 2015
Once‐daily fluticasone furoate 50 mcg in mild‐to‐moderate asthma: a 24‐week placebo‐controlled randomized trial. 69:1522-1530. 2014
Global Allergy Forum and Second Davos Declaration 2013 Allergy: Barriers to cure - challenges and actions to be taken. 69:978-982. 2014
EAACI position statement on asthma exacerbations and severe asthma. 68:1520-1531. 2013
Myeloid dendritic cells type 2 in allergic asthma. 68:1322-1326. 2013
Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. 68:n/a-n/a. 2013
Erratum. 67:712-712. 2012
Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. 67:217-226. 2012
Comparing school environments with and without legislation for the prevention and management of anaphylaxis. 67:131-137. 2012
Dose-response effects of TPI ASM8 in asthmatics after allergen. 66:1242-1248. 2011
Intestinal epithelial cells express galectin-9 in patients with food allergy that plays a critical role in sustaining allergic status in mouse intestine. 66:1038-1046. 2011
Sputum inflammatory cells and allergen-induced airway responses in allergic asthmatic subjects. 66:1075-1080. 2011
How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. 66:765-774. 2011
Immunotherapy with peptides. 66:784-791. 2011
Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. 66:588-595. 2011
Effect of asthma treatment on fitness, daily activity and body composition in children with asthma. 65:1464-1471. 2010
Geographical variations in the prevalence of atopic sensitization in six study sites across Canada. 65:1404-1413. 2010
Lung involvement in Churg-Strauss syndrome as related to the activity of the disease. 65:1484-1485. 2010
Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper. 65:1212-1221. 2010
Reply. 65:1337-1339. 2010
Management of anaphylaxis in primary care: Canadian expert consensus recommendations. 65:no-no. 2010
Heart involvement detected by magnetic resonance in a patient with Churg-Strauss syndrome, mimicking severe asthma exacerbation. 65:1063-1064. 2010
Gaps in anaphylaxis management at the level of physicians, patients, and the community: a systematic review of the literature. 65:435-444. 2010
Sub-lingual Immunotherapy: World Allergy Organization Position Paper 2009. 64:1-59. 2009
The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. 64:1737-1745. 2009
EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. 64:1417-1426. 2009
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria. 64:1427-1443. 2009
Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study. 64:1516-1523. 2009
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’. 64:969-977. 2009
Differential effects of skin nerves on allergic skin inflammation. 64:496-497. 2009
Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. 64:1109-1116. 2009
Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. 64:669-677. 2009
Allergic rhinitis management pocket reference 2008. 63:990-996. 2008
Aspirin tolerance and leukotriene biosynthesis in Churg-Strauss syndrome. 63:949-950. 2008
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. 63:842-853. 2008
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. 63:8-160. 2008
Consensus statements, evidence-based medicine and guidelines in allergic diseases. 63:1-4. 2008
Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. 63:103-111. 2008
Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update. 63:38-46. 2008
Circulating myeloid and plasmacytoid dendritic cells after allergen inhalation in asthmatic subjects. 62:1139-1145. 2007
The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. 62:1101-1110. 2007
Development and validation of an electronic version of the Rhinoconjunctivitis Quality of Life Questionnaire. 62:1091-1093. 2007
Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics. 62:495-503. 2007
Peptide immunotherapy for allergic diseases. 62:325-331. 2007
GINA guidelines on asthma and beyond. 62:102-112. 2007
Effects of intranasal fluticasone and salmeterol on allergen-induced nasal responses. 61:731-736. 2006
Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. 61:537-542. 2006
The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. 60:1269-1274. 2005
Continuing Medical Education: an international reality. 60:739-742. 2005
In memoriam. 60:546-547. 2005
Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. 60:330-337. 2005
Pharmacia Allergy Research Foundation and its Award for Young Scientists in Allergy Research. 60:269-270. 2005
The links between allergen skin test sensitivity, airway responsiveness and airway response to allergen. 60:56-59. 2005
Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study. 59:1097-1101. 2004
The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. 59:4-16. 2004
The promise of and problems with evidence-based medicine for paediatric asthma management. 57:5-14. 2002
Anti-T-cell strategies in the treatment of allergic disease. 57:20-23. 2002
Can the standard gamble and rating scale be used to measure quality of life in rhinoconjunctivitis? Comparison with the RQLQ and SF-36. 57:201-206. 2002
Selective upregulation of a functional beta7 integrin on differentiating eosinophils. 55:865-872. 2000
IL-12 regulates bone marrow eosinophilia and airway eotaxin levels induced by airway allergen exposure. 55:749-756. 2000
The nose, the lung and the bone marrow in allergic inflammation. 54:73-80. 1999
Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. 54:212-219. 1999
The clinical expression of allergy in the lungs. 54:7-14. 1999
The role of shock organs in influencing the clinical expression of allergy. 54:3-6. 1999
Hemopoietic progenitors and cytokines in allergic inflammation. 53:22-26. 1998
Retinoic acid modulation of induced basophil differentiation. 52:1201-1206. 1997
Quality of life in adults and children with asthma and rhinitis. 52:971-977. 1997
A comparison of the efficacy and safety of inhaled corticosteroids in asthma. 52:1-34. 1997
The role of the bone marrow in allergy and asthma. 51:141-148. 1996
Urticaria from allergy to a purified human anti-Rh antibody preparation. 50:981-983. 1995
Microenvironmental influences on inflammatory cell differentiation. 50:25-28. 1995
Comparative Therapeutic Studies with Tilavist. 50:23-29. 1995
CONSEQUENCES - QUALITY ASSURANCE AND SOCIOECONOMICS - DISCUSSION. 48:162-163. 1993
DEFINITION, PREVALENCE AND DIAGNOSIS - DISCUSSION. 48:22-23. 1993
EXAMPLES OF MONITORING OF INFLAMMATION IN ASTHMA - DISCUSSION. 48:110-111. 1993
EXAMPLES OF MONITORING OF INFLAMMATION IN ASTHMA - DISCUSSION. 48:143-145. 1993
Impact of monitoring inflammation on the management of adult asthmatic patients.. 48:153-157. 1993
NEW POSSIBILITIES IN MONITORING INFLAMMATION IN ASTHMA - DISCUSSION. 48:84-86. 1993
PATHOPHYSIOLOGY-INFLAMMATION - DISCUSSION. 48:48-49. 1993
PATHOPHYSIOLOGY-INFLAMMATION - DISCUSSION. 48:62-64. 1993
The definition and diagnosis of asthma.. 48:12-16. 1993
INTERNATIONAL CONSENSUS REPORT ON DIAGNOSIS AND MANAGEMENT OF ASTHMA. 47:R1-&. 1992
The increased number of epithelial mast cells in nasal polyps and adjacent turbinates is not allergy-dependent. 45:370-374. 1990
Geographic variability of house dust mite sensitization profiles: Der p 7 and Der p 23 are major allergens among South African allergic patients 2020
Results of a randomized, double-blind, placebo-controlled, phase 2 study, investigating the safety and efficacy of anti-factor XIIa monoclonal antibody garadacimab (CSL312) for prophylaxis of HAE 2020
Suboptimal response to benralizumab is not associated with inadequate eosinophil suppression 2020
Comparison of responses to nasal and whole lung allergen challenges in mild allergic asthmatic subjects with allergic rhinitis 2019
Crustacean characterization: Identifying the seafood allergic patient, co-morbidities and associated atopic risk factors 2019
Dupilumab reduces oral corticosteroid (OCS) use and severe exacerbations, and improves FEV1 in OCS-dependent, severe asthma with comorbid chronic rhinosinusitis with and without nasal polyps 2019
Oral immunotherapy for peanut allergy: A systematic review and meta-analysis 2019
Seizing the moment: Benefits of immediate in-office penicillin oral challenge in the management of suspected penicillin allergy 2019
The cannabinoid receptor agonist WIN55,212-2 impairs peanut-induced allergic features by promoting the generation of tolerogenic dendritic cells 2019
Benefits of a low fructose/FODMAP diet in suspected fructose intolerance: Follow up and natural history 2018
Food allergy or intolerance: Characterization of fructose intolerance (FI) in an allergy clinic 2018
Hereditary Angioedema Rapid Triage Tool (HAE-RT): Translating research into clinical practice 2018
When it's not just chronic urticaria Recognizing and diagnosing Schnitzler's syndrome 2018
Another brick in the wall: toward a national food allergy strategy for Canada 2017
FoxP3+regulatory B cells were higher in sputum and blood, but lower in bone marrow following whole lung allergen challenge in allergic asthmatics 2017
Global review of epinephrine availability and anaphylaxis management practices amongst patient organization countries 2017
Implementation of stock epinephrine (stock epi) program in malls and food service establishments: A pilot implementation study 2017
Sputum anti-neutrophil cytoplasmic antibodies in eosinophilic granulomatosis and polyangiitis patients with respiratory involvement 2017
Characterization of regulatory B cell phenotypes in the blood and bone marrow following allergen inhalation challenge in mild allergic asthmatics 2016
Food allergen labeling and purchasing habits in the US and Canada 2016
Global knowledge & perceptions of food allergy thresholds in 16 countries 2016
IgE plus B cells increase in the airways following whole lung allergen challenge in mild allergic asthmatics 2016
IgE plus memory B cells subsets are higher in the airways of mild allergic asthmatics compared to healthy controls 2016
Pathogenic sputum autoantibodies in eosinophilic severe asthma: a novel autoimmune endotype 2016
RNA-seq transcriptome analysis of human allergen-specific T cells suggests a role for IL-8 downregulation and modulation of allergic inflammatory cells as one of several potential mechanisms of action of intradermal immunotherapy with Fel d 1 synthetic peptides 2016
The relationship between regulatory B cells and regulatory T cells in the blood and airways of mild allergic asthmatics 2016
Comparison of the treatment effect of house dust mite synthetic peptide immuno-regulatory epitopes in the environmental exposure chamber and field setting two years after a short course of treatment 2015
Mapping the local inflammatory cytokine secretion following a cumulative allergen dose using the Allergic Rhinitis Clinical Investigator Collaborative Nasal Allergen Challenge model 2015
Persistent treatment effect with grass synthetic peptide immuno-regulatory epitopes (Grass-SPIRE) on grass allergy symptoms in the environmental exposure unit after a third season of natural exposure 2015
Whole blood immune transcriptome profiling reveals systemic pathways associated with the mechanism of action of cat-synthetic peptide immunoregulatory epitopes 2015
A short course of synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a reduction in grass allergy symptoms 2014
Blood-based molecular biomarkers of allergen-induced early and late asthmatic responses 2014
Exploring origins of asthma and allergy: early results from the Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort study 2014
Four doses of Der p derived synthetic peptide immuno-regulatory epitopes over 3 months results in a persistent treatment effect at 1 year on symptoms of House Dust Mite allergy 2014
Intracellular IL-1 alpha modulates peanut-induced anaphylaxis in a model of skin sensitisation 2014
Myeloid dendritic cells type 2 in allergic asthma 2013
A pilot study assessing adequacy of epinephrine autoinjector needle length to deliver epinephrine intramuscularly in adult patients with food and venom allergy 2013
Cat-PAD demonstrates sustained, consistent treatment effect on allergic rhinoconjunctivitis in individual catallergic patients 1 and 2 years after four intradermal injections 2013
Current practice with self-administration in the management of hereditary angioedema: the results of a survey 2013
Eosinophil/basophil (Eo/B) progenitors in cord blood (CB) predict respiratory outcomes in early infancy 2013
The Canadian allergy, genes and environment network of centres of excellence: AllerGen 2013
Total nasal symptom scores are reduced in an EEC model of cat allergy two years after administration of four doses of Cat-PAD 2013
Immunotherapy in Canada: perspectives of trainees on their current experience and the immunotherapy training manual 2012
Persistent treatment effect on ocular and nasal symptoms of cat allergy 1 year after four doses of Fel d 1 peptide immunotherapy 2012
Safety and efficacy of Fel d 1 derived peptide immunotherapy in a double-blind, placebo-controlled environmental exposure chamber study 2012
CCR4-acting chemokines contribute to tissue eosinophilia in Churg-Strauss syndrome 2011
Efficacy and safety of fluticasone furoate nasal spray in adult and adolescent subjects with uncomplicated acute rhinosinusitis 2011
Imbalance between Th17 and FoxP3+regulatory T-lymphocytes in Churg-Strauss syndrome 2011
Peculiarities of eicosanoid profile in exhaled breath condensates from patients with Churg-Strauss syndrome 2011
Case report of recurrent throat swelling due to hereditary angioedema despite prophylaxis treated with icatibant 2010
Consistency of effect of fluticasone furoate nasal spray on nasal and ocular symptoms of seasonal allergic rhinitis 2009
Digestibility and allergenicity of native and glycosylated egg white chicken lysozyme 2009
Fluticasone furoate nasal spray improves the individual nasal symptoms (rhinorrhoea, nasal congestion, nasal itching, sneezing) of seasonal allergic rhinitis across four studies 2009
Immunological mechanism of peptide-based immunotherapy in a murine model of acute house dust mite exposure 2009
Immunoreactivity of native and processed egg white chicken ovomucoid after gastroduodenal digestion 2009
Quality of life benefits for patients with seasonal grass pollen-allergic rhinoconjunctivitis receiving ultra short course subcutaneous immunotherapy (uSCIT) with MPL adjuvant 2009
The effect of C5 inhibition by eculizumab on allergen-induced asthmatic responses 2009
The effect of IVX-0142, a heparin-derived hypersulfated disaccharide, on the allergic airway responses in asthma 2008
Burden of allergic rhinitis amongst primary care practitioners and its impact on patient management 2008
Desloratadine significantly reduces nasal congestion and other individual symptoms scores in subjects with intermittent allergic rhinitis: The ACCEPT1 Study in collaboration with GA(2)LEN 2008
Comparative long-term efficacy of ciclesonide versus a fixed combination of fluticasone propionate and salmeterol in mild persistent asthma 2007
Comparative responses to nasal allergen challenge in allergic rhinitic subjects with or without asthma 2007
The development of serum IgE test panels for use by Canadian primary care physicians 2007
Pharmacologic modulation of airway inflammation 1998
Assessing cost-effectiveness in asthma care: building an economic model to study the impact of alternative intervention strategies 1993
Cells and mediators in bronchoalveolar lavage of asthmatic patients: the example of eosinophilic inflammation 1993
Clinical significance of measuring levels of sputum and serum ECP and serum IL-5 in bronchial asthma 1993
Functional and phenotypic characteristics of bronchial epithelial cells obtained by brushing from asthmatic and normal subjects 1993
Impact of monitoring inflammation on the management of adult asthmatic patients 1993
Pathophysiology of asthma 1993
T-cells and endothelial cells in asthma 1993
The definition and diagnosis of asthma 1993

has subject area

1107 Immunology (FoR)
Allergy (Science Metrix)

Allergy: European Journal of Allergy and Clinical Immunology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)